蛋白质精氨酸甲基转移酶5
化学
药物发现
酶
药理学
癌症研究
生物化学
甲基转移酶
生物
基因
甲基化
作者
Christopher R. Smith,Ruth Aranda,Thomas P. Bobinski,David M. Briere,Aaron C. Burns,James G. Christensen,Jeffery Clarine,Lars D. Engstrom,Robin J. Gunn,Anthony Ivetac,Ronald Jean-Baptiste,John M. Ketcham,Masakazu Kobayashi,Jon Kuehler,Svitlana Kulyk,J. David Lawson,Krystal Moya,Peter Olson,Lisa Rahbæk,Nicole C. Thomas
标识
DOI:10.1021/acs.jmedchem.1c01900
摘要
The PRMT5•MTA complex has recently emerged as a new synthetically lethal drug target for the treatment of MTAP-deleted cancers. Here, we report the discovery of development candidate MRTX1719. MRTX1719 is a potent and selective binder to the PRMT5•MTA complex and selectively inhibits PRMT5 activity in MTAP-deleted cells compared to MTAP-wild-type cells. Daily oral administration of MRTX1719 to tumor xenograft-bearing mice demonstrated dose-dependent inhibition of PRMT5-dependent symmetric dimethylarginine protein modification in MTAP-deleted tumors that correlated with antitumor activity. A 4-(aminomethyl)phthalazin-1(2H)-one hit was identified through a fragment-based screen, followed by X-ray crystallography, to confirm binding to the PRMT5•MTA complex. Fragment growth supported by structural insights from X-ray crystallography coupled with optimization of pharmacokinetic properties aided the discovery of development candidate MRTX1719.
科研通智能强力驱动
Strongly Powered by AbleSci AI